Successful capital raise for In Ovo supported by ECBF Demcon, VVNP and Evonik

Transaction
European Circular Bioeconomy Fund (ECBF), Evonik, VisVires New Protein and Demcon have provided equity financing to In Ovo. Rembrandt Mergers & Acquisitions acted as financial advisor to the shareholders of In Ovo.

In Ovo
In Ovo is an Agricultural Technology (AgTech) company that aims to end the culling of male chicks in the value chain of the consumer egg industry. Based on unique and patented biomarker identification, the company has developed a commercially viable and scalable machine that is able to determine the sex of embryos in-egg, within days after fertilisation.

More information is available at: inovo.nl

ECBF, Evonik, VisVires New Protein, Demcon
ECBF is a European venture capital fund that invests in the scale-up of innovative bio-based companies. German chemical concern Evonik’s venture capital fund invests in innovative start-ups globally. Singaporean venture capital fund VisVires New Protein focuses on innovations that have a large impact on the food and feed industry. Demcon is a leading Dutch manufacturer of high technology solutions and innovative products.

More information is available at:
ECBF.vc.
venturing.evonik.com.
demcon.com.
visviresnewprotein.com.